Target
$116 → $115.94
Current stock research snapshot · 7/31/26 26 days old
NVSNovartis
Investment conviction●●○○○2 of 5 · current snapshot
Research target$115.94Current stock price target
Investment thesis statusINTACTLast reviewed 7/31/26
Market cap$301.89BSnapshot value · 7/31/26
Research history
See all NVS changes ↗What changed
Healthspan taxonomy seed — see taxonomy_path
Novartis Q2 2026 earnings; Kisqali breast cancer label expansion; Pluvicto radioligand therapy revenue growth; Entresto LOE defense
Thesis weakens if LOE drag (Entresto -50% cc ~$4.7B annualized loss, Tasigna -57%, Promacta -64%) outruns Kisqali/Kesimpta/Scemblix/Pluvicto growth, or net debt $39.4B (~1.9x op income) constrains M&A capacity. (vault 2026-08)
Neutral — Corporate jet convergence at Bedford MA (Aug 24-26) hints at possible M&A diligence (like 2025 Avidity deal); speculation on Madrigal. [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · 13F 13+/12-×0.5 · short↓0.16
Snapshot · 7/31/26